Peter J. Savino
Vorsitzender bei The Graduate Hospital
Profil
Peter J.
Savino has been a Director of Genaera Corp.
since March 2006.
He is Director of Neuro-Ophthalmology Service of Wills Eye Hospital.
He has been Chairman of the Ophthalmology Department of Graduate Hospital and a Member of the Medical Board since 1980.
Dr. Savino is a Member of the American Academy of Ophthalmology.
He had been Professor of Ophthalmology at Thomas Jefferson Medical College since 1985.
He has served as Ophthalmologist at Thomas Jefferson University Hospital, The Pennsylvania Hospital and Presbyterian Hospital, University of Pennsylvania.
Aktive Positionen von Peter J. Savino
Unternehmen | Position | Beginn |
---|---|---|
Wills Eye Health System & Wills Eye Institute
Wills Eye Health System & Wills Eye Institute Medical/Nursing ServicesHealth Services Wills Eye Health System & Wills Eye Institute is a renowned ophthalmology hospital established in 1832 as the first hospital in the United States specializing in eye care. The hospital is located in Philadelphia, PA. Wills Eye is consistently ranked as one of America's top ophthalmology hospitals by U.S. News & World Report and has the most nationally ranked ophthalmologists in the country. It is also the #1 academic training for its residency program as voted by physicians in the nation. Wills Eye provides a full range of primary and subspecialty eye care services, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, and refractive surgery. The hospital also has a network of seven multi-specialty, ambulatory surgery centers throughout the tristate area. | Corporate Officer/Principal | 01.01.1983 |
The Graduate Hospital
The Graduate Hospital Hospital/Nursing ManagementHealth Services The Graduate Hospital operates as a long term rehabilitation facility. The company was founded in 1917 and is headquartered in Philadelphia, PA. | Vorsitzender | 01.01.1980 |
Ehemalige bekannte Positionen von Peter J. Savino
Unternehmen | Position | Ende |
---|---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Peter J. Savino
Manhattan College | Undergraduate Degree |
Alma Mater Studiorum - Università di Bologna | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Wills Eye Health System & Wills Eye Institute
Wills Eye Health System & Wills Eye Institute Medical/Nursing ServicesHealth Services Wills Eye Health System & Wills Eye Institute is a renowned ophthalmology hospital established in 1832 as the first hospital in the United States specializing in eye care. The hospital is located in Philadelphia, PA. Wills Eye is consistently ranked as one of America's top ophthalmology hospitals by U.S. News & World Report and has the most nationally ranked ophthalmologists in the country. It is also the #1 academic training for its residency program as voted by physicians in the nation. Wills Eye provides a full range of primary and subspecialty eye care services, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, and refractive surgery. The hospital also has a network of seven multi-specialty, ambulatory surgery centers throughout the tristate area. | Health Services |
The Graduate Hospital
The Graduate Hospital Hospital/Nursing ManagementHealth Services The Graduate Hospital operates as a long term rehabilitation facility. The company was founded in 1917 and is headquartered in Philadelphia, PA. | Health Services |